Published on 20 Jan 2023 on Zacks via Yahoo Finance
Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials
Charles River Laboratories International, Inc. CRL recently announced a viral vector contract development and manufacturing organization (CDMO) partnership with Rznomics Inc. South Korea-based biopharmaceutical company Rznomics will leverage Charles River’s viral vector CDMO experience to initiate clinical development of its RNA-based anticancer gene therapy in liver cancer patients.
The latest partnership is a significant stepping stone for Charles River and is expected to solidify its foothold in the global CDMO space. The company’s CDMO services are a part of its Biologics Solutions business, a part of the broader Manufacturing Solutions segment.
Rationale Behind the Tie-Up